New drug aims to help tiniest babies absorb nutrients safely
NCT ID NCT05904626
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called ELGN-2112 in 60 very premature infants (born before 26 weeks) and growth-restricted infants (born 26-32 weeks). The goal is to see if the drug is safe compared to a placebo. If it works, it could help these fragile babies absorb nutrients better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ELGN-2112
- What this could lead to
- If successful, this could point toward a safe treatment to help preterm and growth-restricted infants absorb nutrients better.
- What could go wrong
- This is an early Phase 2 safety study with only 60 infants, so it may not show clear benefit. The drug could still have side effects not yet seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTESTINAL MALABSORPTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laniado Hospital
RECRUITINGNetanya, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.